LCD L38586: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — CGS Administrators
Policy LCD-L38586 · Oncology
New LCD for molecular classifiers in bladder cancer testing.
Code intelligence
Policy changes, MAC LCD updates, and CMS guidance matched to code 0016M.
Signal breakdown
8 shown · 8 total in platform
Critical
0%
High
88%
Routine
13%
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Policy LCD-L38586 · Oncology
New LCD for molecular classifiers in bladder cancer testing.
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
Policy LCD-L38649 · Oncology
New billing guidelines for bladder cancer molecular classifiers.
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
Policy LCD-L38576 · Urology
New LCD for bladder cancer classifiers impacts billing strategies.
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
Policy LCD-L38684 · Urology
Important updates on bladder cancer testing coverage.
Policy LCD-L38647 · Urology
New MolDX may change bladder cancer billing practices.
Audit documentation
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.